Hansa Biopharma AB

Equities

HNSA

SE0002148817

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 11:29:58 2024-04-26 am EDT			5-day change	1st Jan Change
27.32 ^SEK	+0.44%		-6.76%	+4.27%

Apr. 18	Transcript : Hansa Biopharma AB, Q1 2024 Earnings Call, Apr 18, 2024
Apr. 18	Hansa Biopharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Hansa Biopharma and Newbridge Pharmaceuticals Forms Partnership to Enable Supply of Novel Treatment Idefirix to Kidney Transplant Patients in the Middle East and North Africa

January 06, 2024 at 08:00 am EST

Hansa and NewBridge Pharmaceuticals have formed a partnership to enable supply of Hansa's novel treatment Idefirix® to kidney transplant patients in the Middle East and North Africa (MENA) trough NewBridge's capabilities. The new collaboration is rooted in the existing European conditional marketing authorization for Idefirix and pending application for marketing authorization in the respective MENA markets for desensitization treatment in kidney transplantation.

Latest news about Hansa Biopharma AB

Transcript : Hansa Biopharma AB, Q1 2024 Earnings Call, Apr 18, 2024	Apr. 18
Hansa Biopharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 18	CI
Hansa Biopharma Approves SEK372 Million Directed Share Issue	Apr. 12	MT
Hansa Biopharma AB Provides Preliminary Unaudited Revenue Guidance for the First Quarter Ending March 31, 2024	Apr. 02	CI
Hansa Biopharma Hires New CFO	Feb. 22	MT
Hansa Biopharma AB Announces CFO Changes	Feb. 22	CI
Transcript : Hansa Biopharma AB, Q4 2023 Earnings Call, Feb 02, 2024	Feb. 02
Hansa Biopharma AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 02	CI
Hansa Biopharma AB Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 02	CI
Hansa Biopharma and Newbridge Pharmaceuticals Forms Partnership to Enable Supply of Novel Treatment Idefirix to Kidney Transplant Patients in the Middle East and North Africa	Jan. 06	CI
Hansa Biopharma AB Provides Earnings Guidance for the Fourth Quarter and Full Year 2023	Jan. 06	CI
Hansa Biopharma Announces Full Results from 16-HMedIdeS-12 Phase 2 Trial in Patients with Antibody Mediated Rejection Episodes Following Kidney Transplantation	Dec. 14	CI
Hansa Biopharma Nomination Committee Formed	Dec. 13	CI
Hansa Biopharma Announces Positive High-Level Data from the 15-HMedIdeS-09 Phase 2 Trial	Dec. 07	CI
Hansa Biopharma Expects Up to SEK85 Million Annual Savings from Workforce Reduction Plan	Dec. 05	MT
Hansa Biopharma Plans Restructuring to Strengthen Long-Term Competitiveness and Advance Key Deliverables	Dec. 05	CI
Sweden's Hansa Biopharma CFO to Depart in February 2024	Nov. 27	MT
Hahansa Biopharma AB Announces Resignation of Donato Spota as Chief Financial Officer, Effective 28 February 2024	Nov. 27	CI
Transcript : Hansa Biopharma AB, Nine Months 2023 Earnings Call, Oct 26, 2023	23-10-26
Hansa Biopharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-26	CI
Hansa Biopharma's Follow-up Study Shows High Survival Rate for Imlifidase-enabled Kidney Transplant Patients	23-10-17	MT
Hansa Biopharma Announces Results from an Extended Pooled Analysis Using Data from the 17-Hmedides-14 Study, an International Long-Term Follow-Up Study of Patients Who Have Received A Kidney Transplant Following Desensitization with Imlifidase, Showing Sustained Positive Outcomes Out to 5 Years in the Majority of Highly Sensitized Patients Who Received an Imlifidase-Enabled Kidney Transplant	23-10-17	CI
Hansa Biopharma to Finalize Randomization in Late-stage Kidney Study by Mid-2024	23-10-12	MT
Hansa Biopharma Provides Clinical Pipeline Update on Confides Trial	23-10-11	CI
Hansa Biopharma Provides Update on ConfIdeS Phase 3 Trial of Imlifidase in Highly Sensitized Kidney Transplant Patients	23-10-11	CI

Chart Hansa Biopharma AB

Duration

Period

More charts

Company Profile

Hansa Biopharma AB, formerly Hansa Medical AB, is a Sweden-based biopharmaceutical company with focus on immunomodulatory enzymes for treatment and prevention of rare and severe autoimmune conditions and transplant rejection. The Companyâs operations consist of research and development for drug discovery. The Company conducts several projects, among which primary are IdeS (Immunoglobulin G-degrading enzyme of Streptococcus pyogenes) and HBP-assay (Heparin Binding Protein-assay). IdeSâs goal is to enable transplantation that prevents antibody-mediated rejection. HBP-assay is a diagnostic method that aims to predict severe sepsis in patients with infectious disease symptoms. The Companyâs patent portfolio consists of several patent families that geographically cover numerous jurisdictions, including the United States, Europe and Japan.

Sector

Biotechnology & Medical Research

Calendar

2024-05-13 - Capital One Biotech Disruptors Conference

More about the company

Income Statement Evolution

More financial data

Ratings for Hansa Biopharma AB

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

27.32 SEK

Average target price

105 SEK

Spread / Average Target

+284.33%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
HANSA BIOPHARMA AB	+4.27%	137M
IQVIA HOLDINGS INC.	+1.51%	42.75B
MODERNA, INC.	+8.57%	41.34B
LONZA GROUP AG	+49.22%	41.61B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research